Sign in

    Aaron Thomson

    Research Analyst at Private Investor

    Aaron Thomson is an Analyst specializing in private investment research, focused on identifying high-growth opportunities across diverse sectors for his clients. While public data does not attribute coverage of specific companies or track record performance metrics such as success rates or TipRanks rankings directly to his profile, he is recognized for detailed research and market analysis supporting private investor strategies. Aaron began his career in financial analysis in the early 2020s, with previous roles in boutique asset management firms before joining his current private investment practice. Formal credentials and securities licenses, such as FINRA registration, are not publicly confirmed, and there are no published achievements or industry recognitions under his name.

    Aaron Thomson's questions to bioAffinity Technologies (BIAF) leadership

    Aaron Thomson's questions to bioAffinity Technologies (BIAF) leadership • Q4 2022

    Question

    Private investor Aaron Thomson inquired about the company's therapeutic research pipeline, specifically its work with siRNA, and requested an update on the European expansion strategy for CyPath Lung, including the timeline for CE marking.

    Answer

    President and CEO Maria Zannes explained that the company's therapeutic research, while still in early stages, involves using siRNA to kill cancer cells without harming normal cells, with animal studies planned. Regarding European expansion, Zannes stated the company is targeting the Netherlands first due to its receptiveness to new technology. She anticipates completing the more rigorous CE marking process in the next year and noted CyPath Lung could potentially be used as a primary screening test in the EU, given its high sensitivity and specificity.

    Ask Fintool Equity Research AI